The amendment makes minor technical and formatting corrections to the bill, including fixing a typo in a chemical name ("AM-22 087" to "AM-087"), correcting a hyphenation error ("1-10 position" to "1-position"), and cleaning up the legislative language and presentation style. These are substantive corrections that do not alter the bill's core purpose of rescheduling FDA-approved psilocybin as a Schedule IV controlled substance.
26.293.19 26.293.20 101st Legislative Session 1099 2026 South Dakota Legislature House Bill 1099 Introduced by: Representative Rehfeldt Underscores indicate new language. Overstrikes indicate deleted language. ENROLLED AN ACT ENTITLED An Act to reschedule the pharmaceutical composition of crystalline polymorph 1 psilocybin in a drug product approved by the Food and Drug Administration 2 as a Schedule IV controlled substance. 3 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF SOUTH DAKOTA: 4 Section 1. That § 34-20B-14 be AMENDED: 5 34-20B-14. Any material, compound, mixture, or preparation that contains any 6 quantity of the following hallucinogenic substances, their salts, isomers, and salts of 7 isomers, is included in Schedule I, unless specifically excepted, whenever the existence of 8 such the salts, isomers, and salts of isomers is possible within the specific chemical 9 designation: 10 (1) Bufotenine; 11 (2) Diethyltryptamine (DET); 12 (3) Dimethyltryptamine (DMT); 13 (4) 5-methoxy-N, N-Dimethyltryptamine (5-MeO-DMT); 14 (5) 5-methoxy-3, 4-methylenedioxy amphetamine; 15 (6) 4-bromo-2, 5-dimethoxyamphetamine; 16 (7) 4-methoxyamphetamine; 17 (8) 4-methoxymethamphetamine; 18 (9) 4-methyl-2, 5-dimethoxyamphetamine; 19 (10) Hashish and hash oil; 20 (11) Ibogaine; 21 (12) Lysergic acid diethylamide; 22 (13) Mescaline; 23 (14) N-ethyl-3-piperidyl benzilate; 24 (15) N-methyl-3-piperidyl benzilate; 25 (16) 1-(-(2-thienyl)cyclohexyl) piperidine (TCP); 26 26.293.19 26.293.20 2 1099 Underscores indicate new language. Overstrikes indicate deleted language. HB1099 ENROLLED (17) Peyote, except that when used as a sacramental in services of the Native American 1 church, in a natural state which that is unaltered, except for drying or curing and 2 cutting or slicing, it is hereby excepted; 3 slicing; (18) Psilocybin, except the pharmaceutical composition of crystalline polymorph 4 psilocybin in a drug product approved by the United States Food and Drug 5 Administration; 6 (19) Psilocyn; 7 (20) Tetrahydrocannabinol, except that which occurs in industrial hemp as defined in 8 § 38-35-1; in a drug product approved by the United States Food and Drug 9 Administration; or marijuana in its natural and unaltered state; including any 10 compound, except nabilone or compounds listed under a different schedule, 11 structurally derived from 6,6Ν dimethyl-benzo[c]chromene by substitution at the 12 3-position with either alkyl (C3 to C8), methyl cycloalkyl, or adamantyl groups, 13 whether or not the compound is further modified in any of the following ways: 14 (a) By partial to complete saturation of the C-ring; or 15 (b) By substitution at the 1-position with a hydroxyl or methoxy group; or 16 (c) By substitution at the 9-position with a hydroxyl, methyl, or methylhydoxyl 17 group; or 18 (d) By modification of the possible 3-alkyl group with a 1,1Ν dimethyl moiety, a 19 1,1Ν cyclic moiety, an internal methylene group, an internal acetylene 20 group, or a terminal halide, cyano, azido, or dimethylcarboxamido group. 21 Some trade and other names: JWH-051; JWH-057; JWH-133; JWH-359; HHC; AM-22 087; AM-087; AM-411; AM-855, AM-905; AM-906; AM-2389; HU-210; HU-211; HU-243; 23 HU-336; 24 (21) 3, 4, 5-trimethoxy amphetamine; 25 (22) 3, 4-methylenedioxy amphetamine; 26 (23) 3-methoxyamphetamine; 27 (24) 2, 5-dimethoxyamphetamine; 28 (25) 2-methoxyamphetamine; 29 (26) 2-methoxymethamphetamine; 30 (27) 3-methoxymethamphetamine; 31 (28) Phencyclidine; 32 (29) 3, 4-methylenedioxymethamphetamine (MDMA); 33 (30) 3, 4-methylenedioxy-N-ethylamphetamine; 34 (31) N-hydroxy-3, 4-methylenedioxyamphetamine; 35 26.293.19 26.293.20 3 1099 Underscores indicate new language. Overstrikes indicate deleted language. HB1099 ENROLLED (32) 4-methylaminorex (also known as 2-Amino-4-methyl/x-5-phenyl-2-oxazoline); 1 (33) 2,5 Dimethoxy-4-ethylamphetamine; 2 (34) N,N-Dimethylamphetamine; 3 (35) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; 4 (36) Aminorex; 5 (37) 4,4′-Dimethylaminorex (4,4′-DMAR; 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-6 oxazolamine; 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine; 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine); 7 (38) Cathinone and other variations, defined as any compound, material, mixture, 8 preparation or other product unless listed in another schedule or an approved FDA 9 drug, structurally derived from 2-aminopropan-1-one by substitution at the 1-10 position 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not 11 the compound is further modified in any of the following ways: 12 (a) By substitution in the ring system to any extent with alkyl, alkylenedioxy, 13 alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further 14 substituted in the ring system by one or more other univalent substitutents; 15 (b) By substitution at the 3-position with an acyclic alkyl substituent; or 16 (c) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or 17 methoxybenzyl groups or by inclusion of the 2-amino nitrogen atom in a 18 cyclic structure. 19 Some trade or other names: methcathinone, 4-methyl-N-methylcathinone 20 (mephedrone); 3,4-methylenedioxy-N-methylcathinone (methylone); 3,4-21 methylenedioxypyrovalerone 3,4-methylenedioxypyrovalerone (MDPV); Naphthylpyrovalerone (naphyrone); 4-22 flouromethcathinone 4-flouromethcathinone (flephedrone); 4-methoxymethcathinone (methedrone; Bk-23 PMMA); Bk-PMMA); Ethcathinone (N-Ethylcathinone); 3,4-methylenedioxyethcathinone 24 (ethylone); Beta-keto-N-methyl-3,4-benzodioxyolybutanamine (butylone); N,N-25 dimethylcathinone N,N-dimethylcathinone (metamfepramone); Alpha-pyrrolidinopropiophenone (alpha-26 PPP); (alpha-PPP); 4-methoxy-alpha-pyrrolidinopropiophenone (MOPPP); 3,4-27 methylenedioxyalphapyrrolidinopropiophenone 3,4-methylenedioxyalphapyrrolidinopropiophenone (MDPPP); Alpha-28 pyrrolidinovalerophenone Alpha-pyrrolidinovalerophenone (alpha-PVP); 3-fluoromethcathinone; 4Ν-Methyl-alpha-29 pyrrolidinobutiophenone 4Ν-Methyl-alpha-pyrrolidinobutiophenone (MPBP); Methyl-α-pyrrolindinopropiophenone (MPPP); 30 Methyl-α-pyrrolidino-hexanophenone (MPHP); Buphedrone; Methyl-N-31 ethylcathinone; Methyl-N-ethylcathinone; Pentedrone; Dimethylmethcathinone (DMMC); 32 Dimethylethcathinone (DMEC); Methylenedioxymethcathinone (MDMC); 33 Pentylone; Ethylethcathinone; Ethylmethcathinone; Fluoroethcathinone; methyl-34 alpha-pyrrolidinobutiophenone methyl-alpha-pyrrolidinobutiophenone (MPBP); Methylecathinone (MEC); Methylenedioxy-35 26.293.19 Methylenedioxy- 26.293.20 4 1099 Underscores indicate new language. Overstrikes indicate deleted language. HB1099 ENROLLED alpha-pyrrolidinobutiophenone (MDPBP); Methoxymethcathinone (MOMC); 1 Methylbuphedrone (MBP); Benzedrone (4-MBC); Dibutylone (DMBDB); 2 Dimethylone (MDDMA); Diethylcathinone; Eutylone (EBDB); N-ethyl-N-3 Methylcathinone; N-ethyl-N-Methylcathinone; N-ethylbuphedrone, 1-(1,3-benzodioxol-5-yl)2-4 (ethylamino)pentan-1-one 1-(1,3-benzodioxol-5-yl)2-(ethylamino)pentan-1-one (N-Ethylpentylone); 4'-Methyl-alpha-5 pyrrolidinopropiophenone 4'-Methyl-alpha-pyrrolidinopropiophenone (4-MEPPP, MPPP or MαPPP); alpha-6 Pyrrolidinobutiophenone alpha-Pyrrolidinobutiophenone (α-PBP); 1-(1,3-benzodioxol-5-yl)-2-(tert-7 butylamino)propan-1-one 1-(1,3-benzodioxol-5-yl)-2-(tert-butylamino)propan-1-one (Tertylone); 1-(1,3-benzodioxol-5-yl)-2-8 (ethylamino)hexan-1-one 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)hexan-1-one (N-ethyl Hexylone); 1-(1,3-benzodioxol-5-yl)-2-9 (methylamino)pntan-1-one 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pntan-1-one (Pentylone); N-ethylhexedrone (α 10 ethylaminohexanophenone); alpha-pyrrolidinohexanophenone (α-PHP); 4-methyl-11 alpha-ethylaminopentiophenone 4-methyl-alpha-ethylaminopentiophenone (4-MEAP); 4′-methyl-alpha-12 pyrrolidinohexiophenone 4′-methyl-alpha-pyrrolidinohexiophenone (MPHP); alpha-pyrrolidinoheptaphenone (PV8); 4′-13 chloro-alpha-pyrrolidinovalerophenone 4′-chloro-alpha-pyrrolidinovalerophenone (4-chloro-α-PVP); Alpha-PIHP (4-methyl-14 1-phenyl-2-(pyrrolindin-1-yl)pentan-1-one; 15 (4-methyl-1-phenyl-2-(pyrrolindin-1-yl)pentan-1-one; (39) 2,5-Dimethoxy-4-ethylamphetamine (DOET); 16 (40) Alpha-ethyltryptamine; 17 (41) 4-Bromo-2,5-dimethoxy phenethylamine; 18 (42) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7); 19 (43) 1-(3-trifluoromethylphenyl) piperazine (TFMPP); 20 (44) Alpha-methyltryptamine (AMT); 21 (45) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT); 22 (46) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT); 23 (47) Synthetic cannabinoids. Any material, compound, mixture, or preparation that is 24 not listed as a controlled substance in another schedule, is not an FDA-approved 25 drug, and contains any quantity of the following substances, their salts, isomers 26 (whether optical, positional, or geometric), homologues, modifications of the indole 27 ring by nitrogen heterocyclic analog substitution or nitrogen heterocyclic analog 28 substitution of the phenyl, benzyl, naphthyl, adamantly, cyclopropyl, cumyl, or 29 propionaldehyde structure, and salts of isomers, homologues, and modifications, 30 unless specifically excepted, whenever the existence of these salts, isomers, 31 homologues, modifications, and salts of isomers, homologues, and modifications is 32 possible within the specific chemical designation: 33 (a) Naphthoylindoles. Any compound containing a 2-(1- naphthoyl)indole or 3-34 (1-naphthoyl)indole 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the 35 26.293.19 26.293.20 5 1099 Underscores indicate new language. Overstrikes indicate deleted language. HB1099 ENROLLED indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1 1-(N-methyl-2-piperidinhyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-2 (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, 3 (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not 4 further substituted on the indole ring to any extent and whether or not 5 substituted on the naphthyl ring to any extent. 6 Some trade or other names: JWH-015; 1-pentyl-3-(1-naphthoyl)indole 7 (JWH-018); 1-hexyl-3-(1-naphthoyl)indole (JWH-019); 1-butyl-3-(1-8 naphthoyl)indole (JWH-073); 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole 9 (JWH-081); 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122); 1-[2-(4-10 morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); JWH-210; JWH-398; 11 1-pentyl-3-(1-naphthoyl)indole (AM-678); 1-(5-fluoropentyl)-3-(1-12 naphthoyl)indole (AM-2201); WIN 55-212; JWH-004; JWH-007; JWH-009; 13 JWH-011; JWH-016; JWH-020; JWH-022; JWH-046; JWH-047; JWH-048; 14 JWH-049; JWH-050; JWH-070; JWH-071; JWH-072; JWH-076; JWH-079; 15 JWH-080; JWH-082; JWH-094; JWH-096; JWH-098; JWH-116; JWH-120; 16 JWH-148; JWH-149; JWH-164; JWH-166; JWH-180; JWH-181; JWH-182; 17 JWH-189; JWH-193; JWH-198; JWH-211; JWH-212; JWH-213; JWH-234; 18 JWH-235; JWH-236; JWH-239; JWH-240; JWH-241; JWH-258; JWH-262; 19 JWH-386; JWH-387; JWH-394; JWH-395; JWH-397; JWH-399; JWH-400; 20 JWH-412; JWH-413; JWH-414; JWH-415; JWH-424; AM-678; AM-1220; 21 AM-1221; AM-1235; AM-2232, THJ-2201; 22 (b) Naphthylmethylindoles. Any compound containing a 1H-indol-2-yl-(1-23 naphthyl)methane or 1H-indol-3-yl-(1-naphthyl)methane structure with 24 substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, 25 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-26 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-27 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-28 4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted 29 on the indole ring to any extent and whether or not substituted on the 30 naphthyl ring to any extent. 31 Some trade or other names: JWH-175; JWH-184; JWH-185; JWH-192; 32 JWH-194; JWH-195; JWH-196; JWH-197; JWH-199; 33 (c) Phenylacetylindoles. JWH-015; 1-pentyl-3-(1-naphthoyl)indole (JWH-018); 1-hexyl-3-(1-naphthoyl)indole (JWH-019); 1-butyl-3-(1-naphthoyl)indole (JWH-073); 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081); 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122); 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); JWH-210; JWH-398; 1-pentyl-3-(1-naphthoyl)indole (AM-678); 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201); WIN 55-212; JWH-004; JWH-007; JWH-009; JWH-011; JWH-016; JWH-020; JWH-022; JWH-046; JWH-047; JWH-048; JWH-049; JWH-050; JWH-070; JWH-071; JWH-072; JWH-076; JWH-079; JWH-080; JWH-082; JWH-094; JWH-096; JWH-098; JWH-116; JWH-120; JWH-148; JWH-149; JWH-164; JWH-166; JWH-180; JWH-181; JWH-182; JWH-189; JWH-193; JWH-198; JWH-211; JWH-212; JWH-213; JWH-234; JWH-235; JWH-236; JWH-239; JWH-240; JWH-241; JWH-258; JWH-262; JWH-386; JWH-387; JWH-394; JWH-395; JWH-397; JWH-399; JWH-400; JWH-412; JWH-413; JWH-414; JWH-415; JWH-424; AM-678; AM-1220; AM-1221; AM-1235; AM-2232, THJ-2201; (b) Naphthylmethylindoles. Any compound containing a 2-phenylacetylindole 1H-indol-2-yl-(1-naphthyl)methane or 3-34 phenylacetylindole 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the 35 26.293.19 6 1099 Underscores indicate new language. Overstrikes indicate deleted language. indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, cyanoalky, 1-2 (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, 3 (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not 4 further substituted on the indole ring to any extent and whether or not 5 substituted on the phenyl naphthyl ring to any extent. 6 Some trade or other names: 1-cyc lohexylethyl-3-(2-7 methoxyphenylacetyl)indole (SR-18); 1-cyclohexylethyl-3-(2-8 methoxyphenylacetyl)indole (RCS-8); 1-pentyl-3-(2-9 methoxyphenylacetyl)indole (JWH-250); 1-pentyl-3-(2-10 chlorophenylacetyl)indole (JWH-203); JWH-167; JWH-201; JWH-202; JWH-11 204; JWH-205; JWH-206; JWH-207; JWH-208; JWH-209; JWH-237; JWH-12 248; JWH-249; JWH-251; JWH-253; JWH-302; JWH-303; JWH-304; JWH-13 305; JWH-306; JWH-311; JWH-312; JWH-313; JWH-314; JWH-315; JWH-14 316; Cannabipiperidiethanone; 15 (d) Benzoylindoles. JWH-175; JWH-184; JWH-185; JWH-192; JWH-194; JWH-195; JWH-196; JWH-197; JWH-199; (c) Phenylacetylindoles. Any compound containing a 2-(benzoyl)indole 2-phenylacetylindole or 3-16 (benzoyl)indole 3-phenylacetylindole structure with substitution at the nitrogen atom of the 17 26.293.20 6 1099 HB1099 ENROLLED indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 18 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, cyanoalky, 1-19 (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, 20 (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not 21 further substituted on the indole ring to any extent and whether or not 22 substituted on the phenyl ring to any extent. 23 Some trade or other names: 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole 24 (AM-694); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19); Pravadoline 25 (WIN 48,098); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (RCS-4); AM-630; 26 AM-661; AM-2233; AM-1241; 27 (e) Naphthoylpyrroles. 1-cyc lohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18); 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (RCS-8); 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250); 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203); JWH-167; JWH-201; JWH-202; JWH-204; JWH-205; JWH-206; JWH-207; JWH-208; JWH-209; JWH-237; JWH-248; JWH-249; JWH-251; JWH-253; JWH-302; JWH-303; JWH-304; JWH-305; JWH-306; JWH-311; JWH-312; JWH-313; JWH-314; JWH-315; JWH-316; Cannabipiperidiethanone; (d) Benzoylindoles. Any compound containing a 2-(1-naphthoyl)pyrrole 2-(benzoyl)indole or 3-28 (1-naphthoyl)pyrrole 3-(benzoyl)indole structure with substitution at the nitrogen atom of the 29 indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted on the indole ring to any extent and whether or not substituted on the phenyl ring to any extent. Some trade or other names: 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19); Pravadoline (WIN 48,098); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (RCS-4); AM-630; AM-661; AM-2233; AM-1241; (e) Naphthoylpyrroles. Any compound containing a 2-(1-naphthoyl)pyrrole or 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 30 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 31 cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-32 morpholinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl 33 group, whether or not further substituted on the pyrrole ring to any extent 34 and whether or not substituted on the naphthyl ring to any extent. 35 26.293.19 26.293.20 7 1099 Underscores indicate new language. Overstrikes indicate deleted language. HB1099 ENROLLED Some trade or other names: JWH-307; JWH-030; JWH-031; JWH-145; 1 JWH-146; JWH-147; JWH-150; JWH-156; JWH-242; JWH-243; JWH-244; 2 JWH-245; JWH-246; JWH-292; JWH-293; JWH-308; JWH-309; JWH-346; 3 JWH-348; JWH-363; JWH-364; JWH-365; JWH-367; JWH-368; JWH-369; 4 JWH-370; JWH-371; JWH-373; JWH-392; 5 (f) Naphthylmethylindenes. Any compound containing a naphthylideneindene 6 structure with substitution at the 3-position of the indene ring by an alkyl, 7 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-8 piperidinyl)methyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-9 pyrrolidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-10 4-yl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted 11 on the indene ring to any extent and whether or not substituted on the 12 naphthyl ring to any extent. 13 Some trade or other names: JWH-171; JWH-176; JWH-220; 14 (g) Cyclohexylphenols. Any compound containing a 2-(3-15 hydroxycyclohexyl)phenol 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of 16 the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 17 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-18 morpholinyl)ethyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-19 morpholinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl 20 group, whether or not substituted on the cyclohexyl ring to any extent. 21 Some trade or other names: 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-22 hydroxycyclohexyl]-phenol 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47, 497 and homologues, which includes 23 C8); cannabicyclohexanol; CP-55,490; CP-55,940; CP-56,667; 24 (h) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) 25 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol. Some trade or other names: 26 HU-210; 27 (i) 2,3-Dihydro-5-methyl-3-(4-m orpholinylmethyl)pyrrolo[1,2,3-de]-1,4-28 benzoxazin-6-yl]-1-napthalenyl. orpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenyl. Some trade or other names: WIN 55, 212-29 2; 30 212-2; (j) Substituted Acetylindoles. Any compound containing a 2-acetyl indole or 3-31 acetyl 3-acetyl indole structure substituted at the acetyl by replacement of the 32 methyl group with a tetramethylcyclopropyl, adamantyl, benzyl, cumyl, or 33 propionaldehyde substituent whether or not further substituted on the 34 tetramethylcyclopropyl, adamantyl, benzyl, cumyl, or propionaldehyde 35 26.293.19 26.293.20 8 1099 Underscores indicate new language. Overstrikes indicate deleted language. HB1099 ENROLLED substituent to any extent and whether or not further substituted at the 1 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, 2 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-3 morpholinyl)ethyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-4 morpholinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl 5 group whether or not further substituted on the indole ring to any extent. 6 Some trade and or names: (1-Pentylindol-3-yl)-(2,2,3,3-7 tetramethylcyclopropyl)methanone (1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144); (1-(5-fluoropentyl)indol-3-8 yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (1-(5-fluoropentyl)indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (XLR-11); (1-(2-9 morpholin-4-ylethyl)-1H-indol-3-yl)-(2,2,3,3-10 tetramethylcyclopropyl)methanone (1-(2-morpholin-4-ylethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (A-796,260); 1-[(N-methylpiperidin-2-11 yl)methyl]-3-(adamant-1-oyl)indole 1-[(N-methylpiperidin-2-yl)methyl]-3-(adamant-1-oyl)indole (AM-1248); 1-Pentyl-3-(1-12 adamantoyl)indole 1-Pentyl-3-(1-adamantoyl)indole (AB-001 and JWH-018 adamantyl analog); AM-679; (1-13 (4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-14 tetramethylcyclopropyl)methanone (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (FUB-144); 15 (k) Substituted Carboxamide Indole. Any compound containing a 2-carboxamide 16 indole or 3-carboxamide indole structure substituted at the nitrogen of the 17 carboxamide with a tetramethylcyclopropyl, naphthyl, adamantyl, cumyl, 18 phenyl, or propionaldehyde substituent, whether or not further substituted 19 on the tetramethylcyclopropyl, adamantyl, cumyl, naphthyl, phenyl, or 20 propionaldehyde substituent to any extent and whether or not further 21 substituted at the nitrogen atom of the indole ring by an alkyl, haloalkyl, 22 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-23 piperidinyl)methyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-24 pyrrolidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-25 4-yl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group whether or not further substituted 26 on the indole ring to any extent. 27 Some trade and other names: JWH-018 adamantyl carboxamide; STS-135; 28 MN-18; 5-Fluoro-MN-18, 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-29 pyrrolo[2,3-b]pyridine-3-carboxamide 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (5F-CUMYL-P7AICA) ; N-30 (Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-31 APINACA); N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-APINACA); methyl (2R)-2-[[1-(5-fluoropentyl)indazole-3-carbonyl]amino]-32 3,3-dimethylbutanoate (2R)-2-[[1-(5-fluoropentyl)indazole-3-carbonyl]amino]-3,3-dimethylbutanoate (5F-ADB); N-(1-amino-3-methyl-1-oxobutan-2-yl)-33 1-(cyclohexylmethyl)indazole-3-carboxamide N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide (AB-CHMINACA); 1-(4-34 cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (4-CN-35 26.293.19 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (4-CN- 26.293.20 9 1099 Underscores indicate new language. Overstrikes indicate deleted language. HB1099 ENROLLED CUMYL-BUTINACA); N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-1 (cyclohexylmethyl)indazole-3-carboxamide N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide (ADB-CHMINACA or MAB-2 CHMINACA); MAB-CHMINACA); methyl (2S)-2-[[1-[4-fluorophenyl)methyl]indazole-3-3 carbonyl]amino]-3,3-dimethylbutanoate (2S)-2-[[1-[4-fluorophenyl)methyl]indazole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-FUBINACA); methyl 2-(1-4 (cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate (MMB-5 CHMICA); 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate (MMB-CHMICA); methyl (2S)-2-[[1-[4-fluorophenyl)methyl]indazole-3-6 carbonyl]amino]-3-methylbutanoate (2S)-2-[[1-[4-fluorophenyl)methyl]indazole-3-carbonyl]amino]-3-methylbutanoate (AMB-FUBINACA); Methyl 2-(1-(5-7 fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F-AMB); 8 methyl 2-(1-(5-fluoropentyl-1Hindole-3-carboxamido)-3,3-9 dimethylbutaoate 2-(1-(5-fluoropentyl-1Hindole-3-carboxamido)-3,3-dimethylbutaoate (5F-MDMB-PICA); methyl (S)-3,3-dimethyl-2-[(1-(pent-10 4-enlindazole-3-carbonyl)amino]butanoate (S)-3,3-dimethyl-2-[(1-(pent-4-enlindazole-3-carbonyl)amino]butanoate (MDMB-4en-PINACA); methyl 11 2-(1-(4-fluorobutyl)-1H-indazole-3carboxamido)-3,3-dimethylbutanoate 12 (4F-MDMB-BUTINACA); Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-13 carboxamido)-3,3-dimethylbutanoate 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (5F-EDMB-PINACA); Methyl 2-(1-(5-14 fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate S(5F-15 MDMB-PICA); N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-16 carboxamide 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate S(5F-MDMB-PICA); N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (FUB-APINACA); 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-17 1H-indazole-3-carboxamide 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (5F-CUMYL-PINACA); and 18 (l) Substituted Carboxylic Acid Indole. Any compound containing a 1H-indole-2-19 carboxylic 1H-indole-2-carboxylic acid or 1H-indole-3-carboxylic acid substituted at the hydroxyl 20 group of the carboxylic acid with a phenyl, benzyl, naphthyl, adamantyl, 21 cyclopropyl, quinolinyl, isquinolinyl, cumyl, or propionaldehyde substituent 22 whether or not further substituted on the phenyl, benzyl, naphthyl, 23 adamantyl, cyclopropyl, cumyl, quinolinyl, isquinolinyl, or propionaldehyde 24 substituent to any extent and whether or not further substituted at the 25 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, 26 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-27 morpholinyl)ethyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-28 morpholinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, tetrahydropyranylmethyl, benzyl, or halo benzyl group 29 whether or not further substituted on the indole ring to any extent. 30 Some trade and other names: Naphthalen-1-yl 1-(5-fluoropntyl)-1H-indole-31 3-carboxylate 1-(5-fluoropntyl)-1H-indole-3-carboxylate (NM2201); 32 (48) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-6-amine) (MDAI); 33 (49) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E); 34 (50) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D); 35 26.293.19 26.293.20 10 1099 Underscores indicate new language. Overstrikes indicate deleted language. HB1099 ENROLLED (51) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C); 1 (52) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I); 2 (53) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2); 3 (54) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4); 4 (55) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H); 5 (56) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N); 6 (57) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P); 7 (58) Substituted phenethylamine. Any compound, unless specifically exempt, listed as a 8 controlled substance in another schedule or an approved FDA drug, structurally 9 derived from phenylethan-2-amine by substitution on the phenyl ring in any of the 10 following ways: by substitution with a fused methylenedioxy, fused furan, or fused 11 tetrahydrofuran ring system; by substitution with two alkoxy groups; by 12 substitution with one alkoxy and either one fused furan, tetrahydrofuran, or 13 tetrahydropyran ring system; by substitution with two fused ring systems from any 14 combination of the furan, tetrahydrofuran, or tetrahydropyran ring systems; 15 whether or not the compound is further modified in any of the following ways: 16 (a) By substitution on the phenyl ring by any halo, hydroxyl, alkyl, 17 trifluoromethyl, alkoxy, or alkylthio groups; 18 (b) By substitution on the 2-position by any alkyl groups; or 19 (c) By substitution on the 2-amino nitrogen atom with acetyl, alkyl, dialkyl, 20 benzyl, methoxybenzyl, or hydroxybenzyl groups. 21 Some trade and other names: 2-(2,5-dimethoxy-4-22 (methylthio)phenyl)ethanamine 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine (2C-T or 4-methylthio-2,5-23 dimethoxyphenethylamine); 4-methylthio-2,5-dimethoxyphenethylamine); 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine 24 (DOI or 2, 5-Dimethoxy-4-iodoamphetamine); 1-(4-Bromo-2,5-25 dimethoxyphenyl)-2-aminopropane 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane (DOB or 2,5-Dimethoxy-4-26 bromoamphetamine); 2,5-Dimethoxy-4-bromoamphetamine); 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine (DOC 27 or 2,5-Dimethoxy-4-chloroamphetamine); 2-(4-bromo-2,5-dimethoxyphenyl)-N-28 [(2-methoxyphenyl)methyl]ethanamine 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C-B-NBOMe; 25B-NBOMe or 2,5-29 Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine); 2-4-iodo-2,5-30 dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine); 2-4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C-I-NBOMe; 25I-31 NBOMe 25I-NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine); N-(2-32 Methoxybenzyl)-2-(3,4,5-trimethoxypheny N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxypheny (Mescaline-NBOMe or 3,4,5-33 trimethoxy-(2-methoxybenzyl)phenethylamine); 2-(4-chloro-2,5-34 dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine 3,4,5-trimethoxy-(2-methoxybenzyl)phenethylamine); 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C-C-NBOMe; 25C-35 26.293.19 25C- 26.293.20 11 1099 Underscores indicate new language. Overstrikes indicate deleted language. HB1099 ENROLLED NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine); 2-(7-1 Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine (2CB-5-hemiFLY); 2 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine (2C-B-3 FLY); 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-4 yl)ethanamine (2C-B-FLY); 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-yl)ethanamine (2C-B-butterFLY); -(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7-5 tetrahydrobenzo[1,2-b:4,5-bΝ]difuran-4-yl)-2-aminoethane -(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-bΝ]difuran-4-yl)-2-aminoethane (2C-B-FLY-NBOMe); 6 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine (bromo-7 benzodifuranyl-isopropylamine (bromo-benzodifuranyl-isopropylamine or bromo-dragonFLY); -(2-Hydroxybenzyl)-4-iodo-8 2,5-dimethoxyphenethylamine -(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine (2C-I-NBOH or 25I-NBOH); 5-(2-9 Aminoprpyl)benzofuran 5-(2-Aminoprpyl)benzofuran (5-APB); 6(2-Aminopropyl)benzofuran (6-APB); 5-(2-10 Aminopropyl)-2,3-dihydrobenzofuran 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB); 6-(2-Aminopropyl)-2,3,-11 dihydrobenzofuran 6-(2-Aminopropyl)-2,3,-dihydrobenzofuran (6-APDB); para-methoxymethamphetamine (PMMA); 12 (59) Substituted tryptamines. Any compound, unless specifically exempt, listed as a 13 controlled substance in another schedule or an approved FDA drug, structurally 14 derived from 2-(1H-indol-3-yl)ethanamine by mono- or di-substitution of the 15 amine nitrogen with alkyl or alkenyl groups or by inclusion of the amino nitrogen 16 atom in a cyclic structure whether or not the compound is further substituted at 17 the alpha-position with an alkyl group or whether or not further substituted on the 18 indole ring to any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy groups. 19 Some trade and other names: 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT); 4-20 acetoxy-N,N-dimethyltryptamine 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT or O-Acetylpsilocin); 4-hydroxy-N-21 methyl-N-ethyltryptamine 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); 4-hydroxy-N,N-diisopropyltryptamine (4-22 HO-DIPT); (4-HO-DIPT); 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT); 23 (60) Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (CB-13); 24 (61) N-Adamantyl-1-pentyl-1H-Indazole-3-carboxamide (AKB 48); 25 (62) 1-(4-Fluorophenyl)piperazine (pFPP); 26 (63) 1-(3-Chlorophenyl)piperazine (mCPP); 27 (64) 1-(4-Methoxyphenyl)piperazine (pMeOPP); 28 (65) 1,4-Dibenzylpiperazine (DBP); 29 (66) Isopentedrone; 30 (67) Fluoromethamphetamine; 31 (68) Fluoroamphetamine; 32 (69) Fluorococaine; 33 (70) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22); 34 (71) 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid (5 Fluoro-PB-22); 35 26.293.19 26.293.20 12 1099 Underscores indicate new language. Overstrikes indicate deleted language. HB1099 ENROLLED (72) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-1 PINACA); 2 (AB-PINACA); (73) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-3 carboxamide N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5 Fluoro-AB-PINACA); 4 (74) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-5 carboxamide N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA); 6 (75) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide 7 (ADB-PINACA (ADBICA)); 8 (76) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-9 carboxamide N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5 Fluoro-ADB-PINACA (5 Fluoro-ADBICA)); 10 (77) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-11 carboxamide N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (ADB-FUBINACA); 12 (78) N-(1-carbamoyl-2-methyl-propyl)-2-(5-fluoropentyl)-5-(4-fluorophenyl)pyrazole-13 3-carboxamide N-(1-carbamoyl-2-methyl-propyl)-2-(5-fluoropentyl)-5-(4-fluorophenyl)pyrazole-3-carboxamide (5-Fluoro-3,5-AB-PFUPPYCA); and 14 (79) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine). 15 Section 2. That § 34-20B-25 be AMENDED: 16 34-20B-25. The following are included in Schedule IV: 17 (1) Chlordiazepoxide, but not including librax (chlordiazepoxide hydrochloride and 18 clindinium bromide) or menrium (chlordiazepoxide and water soluble esterified 19 estrogens); 20 (2) Clonazepam; 21 (3) Clorazepate; 22 (4) Diazepam; 23 (5) Flunitrazepam; 24 (6) Flurazepam; 25 (7) Mebutamate; 26 (8) Oxazepam; 27 (9) Prazepam; 28 (10) Lorazepam; 29 (11) Triazolam; 30 (12) Any substance that contains any quantity of a benzodiazepine, or salt of 31 benzodiazepine, except substances that are specifically listed in other schedules; 32 (13) Alprazolam; 33 (14) Midazolam; 34 26.293.19 26.293.20 13 1099 Underscores indicate new language. Overstrikes indicate deleted language. HB1099 ENROLLED (15) Temazepam; 1 (16) Cathine; 2 (17) Fencamfamine; 3 (18) Fenproporex; 4 (19) Mefenorex; 5 (20) Pyrovalerone; 6 (21) Propoxyphene; 7 (22) Pentazocine; 8 (23) Diethylpropion; 9 (24) Ethchlorvynol; 10 (25) Ethinamate; 11 (26) Mazindol; 12 (27) Mephobarbital; 13 (28) Methohexitol; 14 (29) Paraldehyde; 15 (30) Pemoline; 16 (31) Petrichloral; 17 (32) Phentermine; 18 (33) Barbital; 19 (34) Phenobarbital; 20 (35) Meprobamate; 21 (36) Zolpidem; 22 (37) Butorphanol; 23 (38) Modafinil, including its salts, isomers, and salts of isomers; 24 (39) Sibutramine; 25 (40) Zaleplon; 26 (41) Dichloralphenazone; 27 (42) Zopiclone, also known as eszopiclone, including its salts, isomers, and salts of 28 isomers; 29 (43) Pregabalin; 30 (44) Lacosamide; 31 (45) Fospropofol, including its salts, isomers, and salts of isomers; 32 (46) Clobazam; 33 (47) Carisoprodol, including its salts, isomers, and salts of isomers; 34 26.293.19 26.293.20 14 1099 Underscores indicate new language. Overstrikes indicate deleted language. HB1099 ENROLLED (48) Ezogabine,[-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl ester], 1 including its salts, isomers, and salts of isomers; 2 (49) Lorcaserin, any material, compound, mixture, or preparation that contains any 3 quantity of the following substances, including its salts, isomers, and salts of 4 isomers, whenever the existence of such salts, isomers, and salts of isomers is 5 possible; 6 (50) Alfaxalone, 5[alpha]-pregnan-3[alpha]-ol-11,20-dione, including its salts, isomers, 7 and salts of isomers; 8 (51) Tramadol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, 9 optical and geometric isomers and salts of these isomers; 10 (52) Suvorexant, including its salts, isomers, and salts of isomers; 11 (53) Eluxadoline,(5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-12 oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-13 methoxybenzoic Eluxadoline,(5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid) including its optical isomers and its salts, isomers, and salts 14 of isomers; 15 (54) Brivaracetam; 16 (55) Solriamfetol (2-amino-3-phenylpropyl carbamate; benzenepropanol, beta-amino-, 17 carbamate (ester)), including its salts, isomers, and salts of isomers whenever the 18 existence of the salts, isomers, and salts of isomers is possible; 19 (56) Brexanolone, (3[alpha]-hydroxy-5[alpha]-pregnan-20-one), including its salts, 20 isomers, and salts of isomers whenever the existence of the salts, isomers, and 21 salts of isomers is possible; 22 (56) Brexanolone, (3[alpha]-hydroxy-5[alpha]-pregnan-20-one), including its salts, isomers, and salts of isomers whenever the existence of the salts, isomers, and salts of isomers is possible; (57) Cenobamate ([(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate; 2H-23 tetrazole-2-ethanol, 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; 24 carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester); 25 (58) Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl)-26 benzamide]; 27 [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl)-benzamide]; (59) Lemborexant, including its salts, isomers, and salts of isomers; 28 (60) Remimazolam; 29 (61) Serdexmethylphenidate, including its salts, isomers, and salts of isomers; 30 (62) Daridorexant, including its salts, isomers, and salts of isomers; 31 (63) Ganaxolone, including its salts; 32 (64) Zuranolone; and 33 (65) The pharmaceutical composition of crystalline polymorph psilocybin in a drug 34 product approved by the United States Food and Drug Administration. 35 26.293.20 15 1099 HB1099 ENROLLED An Act to reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance. I certify that the attached Act originated in the: House as Bill No. 1099 Chief Clerk of the House Speaker of the House Attest: Chief Clerk of the House President of the Senate Attest: Secretary of the Senate House Bill No. 1099 File No. ____ Chapter No. ______ Received at this Executive Office this _____ day of _____________, 2026 at ____________M. By for the Governor The attached Act is hereby approved this ________ day of ______________, A.D., 2026 Governor STATE OF SOUTH DAKOTA, ss. Office of the Secretary of State Filed ____________, 2026 at _________ o'clock __M. Secretary of State By Asst. Secretary of State